Filgotinib

Drug Profile

Filgotinib

Alternative Names: G-146034; GLPG-0634; GS-6034

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; Gilead Sciences
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antirheumatics; Cyclopropanes; Pyridines; Small molecules; Thiamorpholines; Triazoles
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Ankylosing spondylitis; Cutaneous lupus erythematosus; Psoriatic arthritis; Sjogren's syndrome; Uveitis

Most Recent Events

  • 26 Jul 2017 Phase-II clinical trials in Uveitis (Treatment-experienced) in USA (PO) (NCT03207815)
  • 11 Jul 2017 Galapagos initiates enrolment in a phase II trial for Ulcerative colitis in USA (PO) (NCT03201445)
  • 05 Jul 2017 Gilead Sciences plans a phase II trial for Uveitis (Non-infectious, Treatment-experienced) in August 2017 (PO) (NCT03207815)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top